• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Seattle Genetics

Seattle Genetics

  1. All
  2. 3rd Party
  3. Investing
  1. UPDATE: U.S. benchmarks take flight, charting -2-

    UPDATE: U.S. benchmarks take flight, charting -2-

  2. UPDATE: U.S. benchmarks take flight, charting the approach of Dow 23,000

    UPDATE: U.S. benchmarks take flight, charting the approach of Dow 23,000

  3. Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma

    Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma

  4. Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

    Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

  5. Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer

    Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer

12345

©2017 Morningstar Advisor. All right reserved.